Notice of Proposed Sale · 144
BICYCLE THERAPEUTICS PLC
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- BICYCLE THERAPEUTICS PLC
- Issuer CIK
- 0001761612
- SEC file number
- 001-38916
- Phone
- 011441223261503
- Person for whose account securities are to be sold
- Lee Kevin
- Relationships to issuer
- Officer
- Street
- BLOCKS A & B, PORTWAY BUILDING
- Street (continued)
- GRANTA PARK, GREAT ABINGTON
- City
- CAMBRIDGE
- State / country code
- X0
- Postal code
- CB21 6GS
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 9,000 | 31,231.00 | 69,992,871 | 10/02/2026 | Nasdaq | Stifel Nicolaus & Company Inc |
Broker / market maker — proposed row 1, entry 1
- Name
- Stifel Nicolaus & Company Inc
- Street
- 501 N Broadway
- City
- St. Louis
- State / country code
- MO
- Postal code
- 63102
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 10/02/2026 | Restricted Stock Units | Issuer | 12,512 | N | 10/02/2026 | Equity Compensation |
| Common Stock | 10/05/2026 | Restricted Stock Units | Issuer | 3,594 | N | 10/05/2026 | Equity Compensation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Kevin Lee | Common Stock | 07/06/2026 | 1,737 | 7,486.00 |
Seller — prior-sale row 1, entry 1
- Name
- Kevin Lee
- Street
- Blocks A & B Portway Building
- City
- Cambridge
- State / country code
- X0
- Postal code
- CB21 6GS
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 10/02/2026
- Signed
- /s/ Azad Daswani , as a duly authorized representative of STIFEL, as attorney-in-fact for Kevin Lee
Company context
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 20, 2026
- Results of Operations and Financial ConditionJul 30, 2026
- 10-Q filingJul 30, 2026
- Submission of Matters to a Vote of Security HoldersJun 18, 2026
- Other EventsMay 21, 2026